Explore › Intervention › Hypoglycemic Sulfonylureas
Intervention

Hypoglycemic Sulfonylureas

Also known as: Hypoglycemic Sulfonylureas sulfonylureas alone or in combination with other oral diabetes medications (>=75% of year before each landmark)
3 findings 1 paper 4 related entities View in graph →

Related entities

conditions
Non-alcoholic Fatty Liver Disease1
outcomes
Hepatocellular carcinoma1
populations
Type 2 Diabetes Patients1
studys
PMC91075291

Findings (27)

None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →
None
null

In patients with NAFLD and diabetes, sulfonylureas alone and in combination with other oral diabetes medications did not significantly reduce the risk of hepatocellular carcinoma.

Effect: null; HR 0.89; CI: 95% CI 0.73-1.08

Size: HR 0.89 CI: 95% CI 0.73-1.08
PMC9107529
Finding details → · Paper → · Graph →

Papers (1)